To describe DMT cost expenditure and clinical/safety outcomes in a single MS center of an Alemtuzumab cohort of 300 relapsing patients.

The greatest health expenditure for patients with Relapsing-Remitting Multiple Sclerosis (RRMS) in the US is Disease Modifying Therapy (DMT). Alemtuzumab has a unique treatment regimen, allowing for potential significant cost burden reduction, while providing high treatment efficacy.

The first 300 evaluable RRMS patients treated with Alemtuzumab at the Joanne P LaGanke MS Center are described in terms of baseline characteristics, clinical, MRI, and safety outcomes, and DMT cost savings based on annual WAC costs for all other DMT per time point.

Of the 300 subjects, 81% are still followed consistently in clinic. The projected DMT cost savings to date with this cohort exceeds $150,000,000. Of the patients not currently followed at the clinic, most moved, while 18 died. A Listeria meningitis death was the only direct attributable death known to the treatment. Two COVID-related deaths far removed from the treatment occurred. The safety outcomes mirrored those seen in the clinical trials with Alemtuzumab. Sixty percent of the patients had sustained EDSS improvement over the nine-year period of follow-up. Less than ten percent had clinically sustained worsening.

Alemtuzumab administered in this population of RRMS patients provided a massive health cost reduction from DMT use, while maintaining excellent overall clinical outcomes. No unexpected safety issues were observed.